Verrica Pharmaceuticals Inc. (VRCA) — Financial statements
Income statement, balance sheet, and cash flow for Verrica Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 36↑370.2% | 8↑47.7% | 5↓43.3% | 9↓24.7% | 12 | |
| Cost of Revenue | 3↑25.6% | 3↑267.3% | 0.75↑2.9% | 0.73↑53.6% | 0.47 | |
| Gross Profit | 32↑565.9% | 5↑10.2% | 4↓47.3% | 8↓27.9% | 12 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↓25.2% | 12↓41.7% | 20↑66.4% | 12↓23.4% | 16 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 47↑171.8% | 17↓35.5% | 27 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 35↓40.1% | 59↑24.3% | 47↑171.8% | 17↓35.5% | 27 | |
| Other Expenses | 0.00↓100.0% | 0.08↓96.7% | 3 | 0.00↑100.0% | -0.47 | |
| Operating Expenses | 44↓37.7% | 71↑0.9% | 70↑136.9% | 30↓30.2% | 42 | |
| Total Costs & Expenses | 48↓35.3% | 73↑3.7% | 71↑133.7% | 30↓29.3% | 43 | |
| Operating Results | ||||||
| Operating Income | -12↑81.9% | -66↓0.2% | -66↓208.8% | -21↑31.1% | -31 | |
| Depreciation & Amortization | 0.78↓38.5% | 1↑51.8% | 0.84↑16.4% | 0.72↑52.1% | 0.47 | |
| EBITDA | -11↑83.1% | -66↓6.0% | -62↓188.0% | -22↑28.8% | -30 | |
| EBIT | -12↑82.2% | -67↓6.6% | -63↓182.5% | -22↑27.5% | -31 | |
| Interest & Other Income | ||||||
| Net Interest Income | -7↑14.8% | -8↓554.3% | -1↑27.9% | -2↑59.3% | -4 | |
| Interest Income | 0.93↓34.4% | 1↓48.3% | 3↑475.6% | 0.48↑287.0% | 0.12 | |
| Interest Expense | 8↓17.7% | 9↑137.6% | 4↑82.4% | 2↓49.4% | 4 | |
| Non-Operating Income | 0.00↓100.0% | 1↑145.8% | -3↓367.5% | 1↑928.5% | -0.12 | |
| Other Income / Expenses | -6↑44.2% | -11↓762.5% | -1↑61.3% | -3↑23.5% | -4 | |
| Income Before Tax | -18↑76.6% | -77↓14.3% | -67↓173.6% | -24↑30.2% | -35 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -18↑76.6% | -77↓14.3% | -67↓173.6% | -24↑30.2% | -35 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -18↑76.6% | -77↓14.3% | -67↓173.6% | -24↑30.2% | -35 | |
| Bottom-Line Net Income | -18↑76.6% | -77↓14.3% | -67↓173.6% | -24↑30.2% | -35 | |
| EPS (Basic) | -1.68↑88.6% | -14.78↑0.0% | -14.78↓106.1% | -7.17↑44.7% | -12.97 | |
| EPS (Diluted) | -1.68↑88.6% | -14.78↑0.0% | -14.78↓106.1% | -7.17↑44.7% | -12.97 | |
| Weighted Average Shares | 11↑105.6% | 5↑14.3% | 5↑32.7% | 3↑26.3% | 3 | |
| Weighted Average Diluted Shares | 11↑105.6% | 5↑14.3% | 5↑32.7% | 3↑26.3% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.